Last updated: October 2, 2026
Regeneron’s trevogrumab preserved up to 71.8% of the muscle volume otherwise lost on semaglutide over 52 weeks in the Phase 2 COURAGE trial, survodutide cut weight up to 13.1% in Phase 3 type 2 diabetes, and Sanofi paid Regeneron $1 billion upfront for four next generation immunology antibodies.
This report covers life sciences developments from Thursday, October 1, 2026, with primary source verification throughout.
What did Regeneron’s COURAGE trial show about muscle preservation at 52 weeks?
Trevogrumab, Regeneron’s myostatin blocking antibody, preserved a substantial share of the lean mass and muscle volume that patients otherwise lose on semaglutide, with the effect holding through 52 weeks. The data were presented at EASD in Milan and are in press at The Lancet.
Regeneron (REGN) released the full 52 week results of the Phase 2 COURAGE trial on October 1. The release resolves a dose labeling confusion that had circulated in wire coverage earlier this week: COURAGE ran two independent portions. A higher dose portion gave trevogrumab 200 mg or 400 mg alongside semaglutide 2.4 mg for 26 weeks, then continued trevogrumab against placebo for another 26 weeks. A lower dose portion gave trevogrumab 25 mg or 75 mg alongside semaglutide against semaglutide alone for the full 52 weeks. The figures below are from the lower dose portion, which carried the new 52 week comparisons in adults with obesity (BMI of 30 or higher).
| Measure (change from baseline) | Semaglutide + placebo | Trevogrumab 25 mg + semaglutide | Trevogrumab 75 mg + semaglutide |
|---|---|---|---|
| Lean mass by DXA, week 26 | −6.7% | −4.7% (29.9% preserved) | −3.3% (50.7% preserved) |
| Lean mass by DXA, week 52 | −7.3% | −5.8% (20.5% preserved) | −4.2% (42.5% preserved) |
| Muscle volume by MRI, week 26 | −0.88 | −0.32 (63.6% preserved) | −0.24 (72.7% preserved) |
| Muscle volume by MRI, week 52 | −1.03 | −0.29 (71.8% preserved) | −0.32 (68.9% preserved) |
Preservation percentages are Regeneron’s own calculations against the semaglutide plus placebo arm. On safety, 77% of trevogrumab treated participants reported adverse events against 82% on placebo, with nausea, constipation, diarrhea and vomiting the most common events in the trial overall. Regeneron’s next step is a dedicated Phase 2 trial in older adults with obesity and decreased muscle mass and strength, the population where functional outcomes rather than body composition scans will decide whether muscle preservation becomes a reimbursable claim.
One market note, with no cause assigned: Regeneron shares closed at 734.81 on Thursday, down 3.1% by our arithmetic from Wednesday’s 758.27, on the same day the company posted the COURAGE data and received a $1 billion upfront commitment from Sanofi.
How did survodutide perform in the SYNCHRONIZE-2 Phase 3 trial?
Survodutide, the glucagon/GLP-1 dual agonist from Boehringer Ingelheim and Zealand Pharma, cut weight up to 13.1% against 3.1% for placebo over 76 weeks in adults with obesity or overweight and type 2 diabetes, meeting its endpoints but landing below the bar the incretin class set this same week.
The SYNCHRONIZE-2 trial randomized 755 adults to once weekly survodutide 3.6 mg, 6 mg, or placebo for 76 weeks, per the companies’ October 1 release. Alongside the weight result, 79.3% of survodutide treated participants lost at least 5% of body weight against 32.7% on placebo, HbA1c fell up to 1.21 percentage points from a 7.4% baseline against 0.03 points on placebo, and waist circumference fell up to 11.1 cm against 3.5 cm. Discontinuation due to gastrointestinal events ran 18% against 1.2% on placebo. The results were presented at EASD and published in The New England Journal of Medicine.
The publication adds context the release did not lead with. Per Fierce Biotech’s report of the NEJM paper, the treatment policy estimand showed 9.8% weight loss against 3.9% for placebo, 39% of survodutide patients experienced vomiting, and 26% discontinued treatment for adverse events. BMO Capital Markets wrote that survodutide showed a less competitive profile than other agents, a judgment first formed after SYNCHRONIZE-1. Zealand shares fell 11% in Copenhagen trading by midday Thursday, per Fierce Biotech. Boehringer’s cardiovascular outcomes trial reads out later in 2026, and a new Phase 3 called SYNCHRONIZE-T2D has launched in glycemic control.
| Readout this week (all company releases) | Molecule and route | Weight result | Population |
|---|---|---|---|
| EloraTZP Phase 2b, 48 weeks | Amylin + incretin injectable stack | −23.3% at top combo dose | Obesity/overweight + T2D |
| Retatrutide TRIUMPH-2 Phase 3, 80 weeks | Triple agonist injectable | −20.8% at 12 mg | T2D + obesity |
| Survodutide SYNCHRONIZE-2 Phase 3, 76 weeks | Glucagon/GLP-1 dual agonist injectable | −13.1% at top dose | Obesity/overweight + T2D |
Cross trial comparisons carry the usual caveats on populations and durations; the table states each trial’s own figures from its sponsor’s release.
What did Sanofi pay Regeneron for, and what does the alliance expansion include?
Sanofi is paying Regeneron $1 billion upfront, with up to $7 billion in development, regulatory and commercial milestones, for a 50:50 global alliance around four next generation, long acting immunology antibodies aimed at the pathways behind Dupixent.
Per Sanofi’s October 1 release, the four programs are REGN20423, an IL-13 antibody already in Phase 1 for atopic dermatitis; an IL-4xIL-13 bispecific; an IL-4 antibody expected in the clinic in 2027; and an IL-4Rα antibody expected in the clinic in 2027. The companies split development and commercialization costs equally, Regeneron leads R&D, Sanofi leads global commercial, and the existing Dupixent profit sharing arrangement is unchanged. Sanofi also holds an option to add its own lunsekimig, a TSLP/IL-13 bispecific, to the alliance once its Phase 3 COPD studies complete.
The target list is the story: three of the four antibodies work the same IL-4 and IL-13 axis as Dupixent itself, including one aimed at IL-4Rα, Dupixent’s own receptor target. This is a franchise succession plan priced at nine figures upfront, built to extend the alliance’s hold on type 2 inflammation into a long acting era rather than to diversify away from it.
Why did Foghorn Therapeutics fall 18.2% and cut 40% of its staff?
Foghorn and Eli Lilly jointly decided not to advance FHD-909, their lead SMARCA2 inhibitor, after Phase 1 data showed a favorable safety profile but insufficient efficacy. The partners also dropped the selective SMARCA2 degrader program and do not anticipate further collaboration activities.
Foghorn’s October 1 release is unusually direct about the science: FHD-909 (LY4050784) engaged its target at exposures exceeding preclinical thresholds, but the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to advance. The company is cutting roughly 40% of its workforce, extending its cash runway into the second half of 2029, and refocusing on its wholly owned EP300 degrader, an oral immunology and inflammation program, and a CBP degrader. Foghorn shares closed at 2.92, down 18.2% by our arithmetic from Wednesday’s 3.57.
The readacross matters beyond one company. SMARCA2 selective inhibition in SMARCA4 mutant cancers was among the cleanest genetic arguments in the synthetic lethality field after PARP, and a well run test with a major partner has now returned a negative answer on efficacy, not on chemistry or safety. Programs leaning on similar paralog logic will face sharper questions about whether target engagement converts to tumor response.
What did Cullinan and Taiho submit to the FDA for zipalertinib?
Cullinan Therapeutics and Taiho initiated a rolling NDA submission on Thursday evening for zipalertinib plus platinum chemotherapy in first line EGFR exon 20 insertion non small cell lung cancer, under the FDA’s Real Time Oncology Review program, with completion expected by year end.
The submission rests on the Phase 3 REZILIENT3 interim analysis, where zipalertinib plus chemotherapy delivered median progression free survival of 14.5 months against 8.5 months for chemotherapy alone, per the companies’ release, which crossed at 7:30 pm ET after Thursday’s close. Friday is the first reaction session. Cullinan is eligible for a $30 million milestone on a second line US approval and $100 million on a first line approval. The separate monotherapy NDA remains under review with a February 27, 2027 action date, so zipalertinib now has two US regulatory tracks running at once.
What else moved in medtech, policy and capital markets on October 1?
Axogen closed its BioCircuit acquisition after Thursday’s close, adding NerveTape, the first FDA cleared device for sutureless peripheral nerve repair. The GENEROUS final state count remains unpublished two days past its signing deadline, and Oura postponed its IPO.
Axogen/BioCircuit. The completion release crossed at 5:19 pm ET, making Friday the first reaction session. NerveTape gives Axogen a differentiated hardware claim in peripheral nerve repair, and the close resolves a deal that had sat on the fourth quarter calendar.
GENEROUS. As of Thursday night, CMS had not published a final signed state count for its GENEROUS Medicaid drug pricing model, whose signing deadline was September 30. We checked the CMS newsroom index at roughly 8:15 pm Pacific on October 1; the most recent GENEROUS release remains September 18, which reported 40 states plus Puerto Rico signed, all 50 states plus DC and Puerto Rico applied, and a White House projection of $64.3 billion in savings over ten years.
US-China tariffs. The US-China Board of Trade recommended reduced tariff treatment covering roughly $30 billion of imports on each side, with medical devices explicitly included among US exports gaining improved access, per MedTech Dive’s September 30 report quoting US Trade Representative Jamieson Greer. No reduction amounts or implementation dates were specified.
Capital cycle. Oura postponed its planned IPO, citing market uncertainty, after filing to raise up to $2.2 billion, per MedTech Dive’s September 29 report; the company reported $907.9 million in fiscal 2025 revenue and 5.7 million paid members, figures that are Oura’s own as reported. Separately, BioSpace tallied Q3 biopharma M&A at just under $30 billion across 22 transactions, bringing the year to roughly $156.9 billion across 74 deals, with Vertex’s $10 billion Crinetics acquisition from July the quarter’s largest.
Novo liver data. A post hoc pooled analysis of the STEP UP and STEP UP T2D trials, released by Novo Nordisk on October 1, showed injectable semaglutide reduced liver fat from 8.8% to 3.1% at week 72 in a 55 participant imaging subgroup, with 88.5% of those starting above the 5% threshold reaching normal levels. Novo states the analysis was post hoc and exploratory.
How did the week’s delivery layer theme resolve?
The week’s through line held: the molecules are converging while delivery and composition diverge. Survodutide’s 13.1% confirmed the convergence from below, and COURAGE opened the next axis of divergence, which is what the lost weight is made of.
| Day | Evidence | Delivery layer verdict |
|---|---|---|
| Monday | Kodiak DAYBREAK six month dosing win; Mirum AZURE-1 interval cost | Dosing interval split: it can win a Phase 3 or charge a price |
| Wednesday | Retatrutide TRIUMPH-2, −20.8% | The molecule axis ceiling moved up |
| Thursday | EloraTZP −23.3% with titration design focus; ACHIEVE-4 oral CV safety; OCTANE pill switchers kept losing | Titration schedules and oral delivery became the battlegrounds |
| Friday | Survodutide −13.1%; COURAGE muscle preservation through 52 weeks | A converging molecule missed the bar; composition is the new differentiator |
Which stocks moved on the day’s news?
Five closes carried a story on Thursday. All percentages are our arithmetic from exchange settled closes.
| Ticker | Close (Oct 1) | Move | The story |
|---|---|---|---|
| FHTX | 2.92 | −18.2% | The Lilly collaboration ended on efficacy; 40% staff cut, runway to H2 2029 |
| REGN | 734.81 | −3.1% | Fell on the day it posted COURAGE and banked $1B upfront from Sanofi; cause not assigned |
| LLY | 1,149.85 | −0.6% | Second session after the retatrutide week: the −2.3% first reaction did not extend |
| KOD | 98.46 | +3.9% | Fourth straight gain extending the DAYBREAK repricing |
| QURE | 23.37 | −3.3% | The stabilization after the 48 month decay is eroding at the margin ahead of the ~November BLA acceptance decision |
Frequently asked questions
What is trevogrumab and how does it work?
Trevogrumab is Regeneron’s antibody that blocks myostatin, a protein that limits muscle growth. Blocking myostatin during GLP-1 induced weight loss is intended to preserve lean mass while fat is lost.
Did trevogrumab’s muscle preservation last the full 52 weeks of COURAGE?
Yes, with some decay on the DXA measure. Lean mass preservation at the 75 mg dose went from 50.7% at week 26 to 42.5% at week 52, while MRI muscle volume preservation held near 70% at both timepoints.
Why were earlier COURAGE dose figures confusing?
The trial ran two independent portions with different doses: 200 mg and 400 mg in a higher dose portion reported in 2025, and 25 mg and 75 mg in the lower dose portion that carried this week’s 52 week data. Wire coverage earlier in the week mixed the two.
Is trevogrumab approved?
No. COURAGE is a Phase 2 trial. Regeneron’s next step is another Phase 2 in older adults with obesity and decreased muscle mass and strength.
What is survodutide and who develops it?
Survodutide is a once weekly injectable glucagon/GLP-1 receptor dual agonist developed by Boehringer Ingelheim under license from Zealand Pharma. SYNCHRONIZE-2 is its Phase 3 trial in obesity or overweight with type 2 diabetes.
How much weight did survodutide patients lose in SYNCHRONIZE-2?
Up to 13.1% at 76 weeks against 3.1% for placebo in the sponsors’ primary analysis. Fierce Biotech reports the NEJM publication’s treatment policy estimand at 9.8% against 3.9%.
How does survodutide compare with tirzepatide or retatrutide?
No head to head trials exist. On each sponsor’s own figures this week, EloraTZP reported 23.3% at 48 weeks in Phase 2 and retatrutide 20.8% at 80 weeks in Phase 3, both in diabetes containing populations, against survodutide’s 13.1% at 76 weeks.
What did Sanofi and Regeneron agree to on October 1?
Sanofi pays Regeneron $1 billion upfront and up to $7 billion in milestones for a 50:50 alliance on four long acting immunology antibodies targeting IL-13, IL-4 and IL-4Rα, with an option on Sanofi’s lunsekimig after Phase 3 COPD data.
Does the new Sanofi/Regeneron deal change Dupixent economics?
No. The companies state the existing Dupixent profit sharing arrangement is unchanged. The new programs sit in a separate 50:50 structure with shared costs.
Why did Foghorn Therapeutics cut 40% of its workforce?
Foghorn and Lilly jointly stopped FHD-909 and the SMARCA2 degrader collaboration after Phase 1 efficacy fell short. Foghorn is conserving cash, extending its runway into the second half of 2029 while it refocuses on wholly owned programs.
What does the FHD-909 outcome mean for synthetic lethality drug development?
It is a clean negative: the drug hit its target safely but tumors did not respond at the level required. Programs built on similar paralog based genetic logic now face harder questions about converting target engagement into efficacy.
What is zipalertinib and what did Cullinan and Taiho file?
Zipalertinib is an EGFR exon 20 insertion directed therapy for non small cell lung cancer. The partners began a rolling NDA for first line use with chemotherapy under Real Time Oncology Review, on REZILIENT3 data showing 14.5 versus 8.5 months median progression free survival.
When will the FDA decide on zipalertinib?
Two tracks are running. The earlier monotherapy NDA has a February 27, 2027 action date. The new first line rolling submission is expected to complete by year end 2026, with its review clock set after completion.
Has the GENEROUS model published its final state count?
Not as of the night of October 1. The signing deadline was September 30; CMS’s most recent release, dated September 18, reported 40 states plus Puerto Rico signed and all 50 states plus DC and Puerto Rico applied.
What happened to the Oura IPO?
Oura postponed it, citing market uncertainty, per MedTech Dive. The company had filed to raise up to $2.2 billion and says it can choose its moment; its registration statement has not been declared effective.
Sources
Primary sources (October 1, 2026 unless noted): Regeneron press release, Phase 2 COURAGE 52 week results (GlobeNewswire); Zealand Pharma and Boehringer Ingelheim press releases, SYNCHRONIZE-2 results (GlobeNewswire); Sanofi press release, alliance expansion with Regeneron (sanofi.com); Regeneron press release, alliance expansion (GlobeNewswire); Foghorn Therapeutics press release, FHD-909 and strategic update; Cullinan Therapeutics/Taiho press release, zipalertinib rolling NDA initiation; Axogen press release, BioCircuit acquisition completion; Novo Nordisk press release, STEP UP pooled liver fat analysis; CMS press release, GENEROUS participants (September 18, 2026); exchange settled closing prices, October 1, 2026.
Trade press and attributed: Fierce Biotech (SYNCHRONIZE-2 NEJM figures, Zealand Copenhagen trading, BMO commentary, October 1); The New England Journal of Medicine (SYNCHRONIZE-2 publication, as reported); HCPLive and RTTNews (release corroboration); MedTech Dive (US-China Board of Trade, September 30; Oura IPO delay, September 29); BioSpace (Q3 M&A tally, October 1).
Related coverage
Read our report on Lilly’s EloraTZP Phase 2 results and Foundayo’s cardiovascular safety test, our analysis of retatrutide’s TRIUMPH-2 data and uniQure’s 48 month Huntington’s results, and our coverage of Kodiak’s DAYBREAK win and the dosing interval split.
